{
    "Trade/Device Name(s)": [
        "LIAISON BRAHMS PCT II GEN assay",
        "LIAISON Control BRAHMS PCT II GEN",
        "LIAISON BRAHMS PCT II GEN Verifiers",
        "LIAISON BRAHMS PCT II GEN"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K173683",
    "Predicate Device Reference 510(k) Number(s)": [
        "K162827",
        "K141463"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PMT",
        "NTM",
        "JJX",
        "PRI"
    ],
    "Summary Letter Date": "November 30, 2017",
    "Summary Letter Received Date": "December 1, 2017",
    "Submission Date": "November 30, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "Procalcitonin Assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "Procalcitonin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Quality control material",
        "Verification kit"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON BRAHMS PCT II GEN assay, control, and verifiers for quantitative determination of procalcitonin in serum and lithium heparin plasma using chemiluminescent immunoassay on the LIAISON Analyzer",
    "Indications for Use Summary": "Aids in risk assessment of ICU patients for progression to severe sepsis and septic shock, 28-day mortality risk assessment in severe sepsis/septic shock, decision making on antibiotic therapy for lower respiratory tract infections, and antibiotic discontinuation for suspected/confirmed sepsis; controls and verifiers for quality monitoring of the assay",
    "fda_folder": "Microbiology"
}